Germany · Delayed Price · Currency is EUR Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of EUR 625.17 million. The enterprise value is 644.66 million.
| Market Cap | 625.17M |
| Enterprise Value | 644.66M |
Important Dates
The next estimated earnings date is Monday, March 9, 2026.
| Earnings Date | Mar 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 231.46M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.46% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 3.53% |
| Owned by Institutions (%) | 62.66% |
| Float | 188.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.65 |
| PB Ratio | -8.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.84 |
| EV / Sales | 17.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.77 |
Financial Position
The company has a current ratio of 3.28
| Current Ratio | 3.28 |
| Quick Ratio | 3.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.28 |
| Interest Coverage | -13.97 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -34.25% |
| Return on Invested Capital (ROIC) | -50.67% |
| Return on Capital Employed (ROCE) | -104.52% |
| Revenue Per Employee | 258,929 |
| Profits Per Employee | -917,904 |
| Employee Count | 145 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.05M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +337.04% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +337.04% |
| 50-Day Moving Average | 2.22 |
| 200-Day Moving Average | 1.53 |
| Relative Strength Index (RSI) | 63.58 |
| Average Volume (20 Days) | 21 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.69 |
Income Statement
In the last 12 months, Gossamer Bio had revenue of EUR 37.54 million and -133.10 million in losses. Loss per share was -0.59.
| Revenue | 37.54M |
| Gross Profit | 37.54M |
| Operating Income | -130.69M |
| Pretax Income | -135.15M |
| Net Income | -133.10M |
| EBITDA | -130.59M |
| EBIT | -130.69M |
| Loss Per Share | -0.59 |
Balance Sheet
The company has 153.60 million in cash and 172.91 million in debt, giving a net cash position of -19.31 million.
| Cash & Cash Equivalents | 153.60M |
| Total Debt | 172.91M |
| Net Cash | -19.31M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -70.17M |
| Book Value Per Share | -0.30 |
| Working Capital | 120.92M |
Cash Flow
In the last 12 months, operating cash flow was -135.03 million and capital expenditures -67,332, giving a free cash flow of -135.10 million.
| Operating Cash Flow | -135.03M |
| Capital Expenditures | -67,332 |
| Free Cash Flow | -135.10M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -348.10% |
| Pretax Margin | -359.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.46% |
| Shareholder Yield | -0.46% |
| Earnings Yield | -21.29% |
| FCF Yield | -21.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gossamer Bio has an Altman Z-Score of -10.1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.1 |
| Piotroski F-Score | n/a |